NO20045147L - Behandling av hypertensjon hos kvinner som far hormonerstatningsbehandling - Google Patents

Behandling av hypertensjon hos kvinner som far hormonerstatningsbehandling

Info

Publication number
NO20045147L
NO20045147L NO20045147A NO20045147A NO20045147L NO 20045147 L NO20045147 L NO 20045147L NO 20045147 A NO20045147 A NO 20045147A NO 20045147 A NO20045147 A NO 20045147A NO 20045147 L NO20045147 L NO 20045147L
Authority
NO
Norway
Prior art keywords
replacement therapy
hormone replacement
hypertension
treatment
women undergoing
Prior art date
Application number
NO20045147A
Other languages
English (en)
Norwegian (no)
Inventor
Adel H Karara
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20045147L publication Critical patent/NO20045147L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20045147A 2002-04-26 2004-11-25 Behandling av hypertensjon hos kvinner som far hormonerstatningsbehandling NO20045147L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37543902P 2002-04-26 2002-04-26
PCT/US2003/012596 WO2003090755A1 (en) 2002-04-26 2003-03-24 Treatment of hypertension in women receiving hormone replacement therapy

Publications (1)

Publication Number Publication Date
NO20045147L true NO20045147L (no) 2005-01-18

Family

ID=29270642

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045147A NO20045147L (no) 2002-04-26 2004-11-25 Behandling av hypertensjon hos kvinner som far hormonerstatningsbehandling

Country Status (23)

Country Link
US (1) US20040034001A1 (de)
EP (2) EP1499323A1 (de)
JP (1) JP2005528408A (de)
KR (1) KR20040104632A (de)
CN (1) CN1649596A (de)
AU (2) AU2003239162A1 (de)
BR (1) BR0309780A (de)
CA (1) CA2483554A1 (de)
CR (1) CR7571A (de)
EC (1) ECSP045456A (de)
HK (1) HK1079997A1 (de)
HR (1) HRP20041121A2 (de)
IL (1) IL164808A0 (de)
ME (1) MEP35908A (de)
MX (1) MXPA04010682A (de)
NO (1) NO20045147L (de)
NZ (1) NZ548754A (de)
PL (1) PL372055A1 (de)
RS (1) RS93804A (de)
RU (1) RU2373940C2 (de)
UA (1) UA87437C2 (de)
WO (1) WO2003090755A1 (de)
ZA (1) ZA200409548B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE102004016779A1 (de) * 2004-04-01 2006-01-19 Schering Ag Drospirenonhaltige Zubereitungen zur transdermalen Anwendung
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
US20090035373A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same
US20090035374A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same
US20130137664A1 (en) * 2010-04-15 2013-05-30 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US5001113A (en) 1987-10-14 1991-03-19 Merck & Co., Inc. Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA
US6300362B1 (en) 1990-07-25 2001-10-09 Novartis Ag (Formerly Sandoz Ltd.) Stabilized pharmaceutical compositions comprising acid donors
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US6083528A (en) 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
KR0156678B1 (ko) 1996-01-11 1998-10-15 이상윤 안지오텐신 전환효소 저해제
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
KR101019361B1 (ko) * 1999-08-31 2011-03-07 바이엘 쉐링 파마 악티엔게젤샤프트 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
ES2332226T3 (es) * 2000-01-18 2010-01-29 Bayer Schering Pharma Aktiengesellschaft Composiciones farmaceuticas que comprenden drospirenona.
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
CA2419256A1 (en) * 2000-08-28 2002-03-07 Kenton N. Fedde Use of an aldosterone receptor antagonist to improve cognitive function
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins

Also Published As

Publication number Publication date
MEP35908A (en) 2011-02-10
ECSP045456A (es) 2005-01-28
HRP20041121A2 (en) 2005-02-28
CA2483554A1 (en) 2003-11-06
RU2004134571A (ru) 2005-07-10
HK1079997A1 (zh) 2006-04-21
CR7571A (es) 2006-02-07
AU2003239162A1 (en) 2003-11-10
JP2005528408A (ja) 2005-09-22
KR20040104632A (ko) 2004-12-10
NZ548754A (en) 2008-06-30
EP1982719A1 (de) 2008-10-22
US20040034001A1 (en) 2004-02-19
RS93804A (sr) 2006-10-27
UA87437C2 (ru) 2009-07-27
CN1649596A (zh) 2005-08-03
PL372055A1 (en) 2005-07-11
AU2008203497A1 (en) 2008-08-28
RU2373940C2 (ru) 2009-11-27
BR0309780A (pt) 2005-03-22
EP1499323A1 (de) 2005-01-26
IL164808A0 (en) 2005-12-18
ZA200409548B (en) 2010-05-26
WO2003090755A1 (en) 2003-11-06
MXPA04010682A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
NO20045147L (no) Behandling av hypertensjon hos kvinner som far hormonerstatningsbehandling
Kalra et al. Surgical treatment of venous ulcers: role of subfascial endoscopic perforator vein ligation
ATE312635T1 (de) Ventilanordnung
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
WO2006015354A3 (en) Electrosurgical systems and methods
DE60326490D1 (de) Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung
NO20060002L (no) Enhetssammensetning av FSH og hCG
DK1202727T3 (da) Anvendelse af agonister af GABAB-receptorer og farmaceutisk acceptable derivater deraf til behandling for at opnå fortsat nikotinafholdenhed hos nikotinafhængige patienter
DK1525215T3 (da) Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner
SE9902597D0 (sv) New use
HUP0300339A2 (hu) Fulvesztrant felhasználása rezisztens emlőrák kezelésében
CN203647436U (zh) 一种包皮环切器
MXPA03009448A (es) Inhibidores de aromatasa para tratamiento de infertilidad.
Scarabin Risk of venous thrombosis with hormone replacement therapy
MXPA03009447A (es) Inhibidor de aromatasa de dosis unica para tratamiento de infertilidad.
MXPA03009446A (es) Inhibicion de aromatasa para mejorar reproduccion asistida.
RS37804A (en) Use of n,n-diethyl-2-/-4-(phenylmethyl)- phenoxy/ethanamine monohydrochloride (dppe)in cancer therapy
DK2014290T3 (da) Anvendelse af tenatoprazol til behandling af gastroøsofageal refluks
Chong-yang et al. Evaluation of harmonic scalpel assisted extracapsular dissection for benign parotid tumors
AR039477A1 (es) Terapia de reemplazo hormonal
CN201676388U (zh) 硝酸甘油气雾剂辅助给药装置
AU2003209091A1 (en) Occluding and stablizing medical device
Kumar et al. A CASE REPORT ON THE ROLE OF LEECH THERAPY IN STASIS DERMATITIS
STOHR Oral hormone therapy in anovulatory bleeding
UA40717A (uk) Спосіб лікування хворих з шлунковою кровотечею

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application